A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets
Latest Information Update: 04 Nov 2022
At a glance
- Drugs TQB 3558 (Primary)
- Indications Bone metastases; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
Most Recent Events
- 30 Jun 2020 Status changed from not yet recruiting to recruiting.
- 01 Jun 2020 New trial record